Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: A meta-analysis of > 35,000 patients

International Journal of Cardiology

Volumn 173, Issue 2, 2014, Pages 197-203

  Peck, Kah Yong ^a   Lim, Yuan Zhi ^a   Hopper, Ingrid ^a   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Drugs; Implantable cardioverter defibrillators; Meta analysis; Sudden death; Systolic heart failure

Indexed keywords

ALISKIREN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRIC CARBOXYMALTOSE; IVABRADINE; MINERALOCORTICOID ANTAGONIST; OMEGA 3 FATTY ACID; PLACEBO;

ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; META ANALYSIS; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SUDDEN CARDIAC DEATH; TREATMENT RESPONSE; AGED; COMPARATIVE STUDY; DEATH, SUDDEN, CARDIAC; DRUG THERAPY; HEART FAILURE, SYSTOLIC; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; MORTALITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; THERAPY;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE, SYSTOLIC; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84898880677     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.02.014     Document Type: Article

References (30)

1. J.J.V. McMurray Systolic heart failure N Engl J Med 362 2010 228 238
2. R.E. Lane, M.R. Cowie, and A.W.C. Chow Prediction and prevention of sudden cardiac death in heart failure Heart 91 5 2005 674 680
3. G.H. Bardy, K.L. Lee, and D.B. Mark et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 3 2005 225 237
4. M.R. Bristow, L.A. Saxon, and J. Boehmer et al. Cardiac-resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 350 21 2004 2140 2150
5. A. Moss, W. Zareba, and J. Hall et al. Prophylactic implantation of defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med 346 12 2002 877 883
6. J.E. Poole, M.J. Gleva, and T. Mela et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures Circulation 122 2010 1553 1561
7. P. Alter, S. Waldhans, E. Plachta, R. Moosdorf, and W. Grimm Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients Pacing Clin Electrophysiol 28 9 2005 926 932
8. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 J.P.T. Higgins, D.G. Aktman, 2008 The Cochrane Collaboration
9. Review Manager (RevMan) Version 5.2 2012 The Nordic Cochrane Centre, The Cochrane Collaboration Copenhagen
10. D. LA Moher, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement BMJ 339 2009 b2535
11. D.G. Altman, and J.M. Bland Interaction revisited: the difference between two estimates BMJ 326 2003 219
12. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
13. J.N. Cohn, G. Tognoni, and Valsartan Heart Failure Trial Investigators A randomized trial of the angitoensin-receptor blocker Valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
14. C.B. Granger, J.J. McMurray, and S. Yusuf et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
15. J.J. McMurray, J. Ostergren, and K. Swedberg et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
16. B. Pitt, F. Zannad, and W. Remme et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 10 1999 709 717
17. B. Pitt, W. Remme, and F. Zannad et al. Eplerenone, a selective aldoserone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
18. F. Zannad, J.J. McMurray, and H. Krum et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
19. K. Swedberg, M. Komajda, and M. Bohm et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 2010 875 885
20. GISSI-HF investigators Effect of n-3polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1223 1230
21. S. Anker, J. Comin, and G. Filippatos et al. Ferric carboxymaltose in patients wtih heart failure and iron deficiency N Engl J Med 361 2009 2436 2448
22. M. Gheorghiade, M. Bohm, and S. Greene et al. Effect of Aliskiren on post discharge mortality and heart failure readmissions among patients hospitalized for heart failure. The ASTRONAUT Randomized Trial JAMA 309 11 2013 1125 1135
23. A. Kadish, A. Dyer, and J. Daubert et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy N Engl J Med 350 2004 2151 2158
24. R. Deo, and C.M. Albert Epidemiology and genetics of sudden cardiac death Circulation 125 2012 620 637
25. M.J. Domanski, D.V. Exner, C.B. Borkowf, N.L. Geller, Y. Rosenberg, and M.A. Pfeffer Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials J Am Coll Cardiol 33 3 1999 598 604
26. L.M. Friedman, R.P. Byington, R.J. Capone, C.D. Furberg, S. Goldstein, and E. Lichstein Effect of propanolol in patients with myocardial infarction and ventricular arrhythmia J Am Coll Cardiol 7 1 1986 1 8
27. M. Albaghdadi, G. Mihai, and B. Pitt Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes Eur Heart J 32 2011 2626 2633
28. X. Gao, L. Peng, C. Adhikari, J. Lin, and Z. Zuo Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure J Card Fail 13 2007 170 177
29. A. Dawson, J.I. Davies, and A.D. Struthers The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade Expert Rev Cardiovasc Ther 2 1 2004 29 36
30. B. Pitt, and G.S. Pitt Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death Circulation 115 2007 2976 2982